A.N. BOYKO¹, O.V. BYKOVA², S.A. SIVERTSEVA³

¹Pirogov Russian National Research Medical University, 1 Ostrovityanov Str., Moscow, Russian Federation, 117342

²Scientific-practical Center for Children’s Psychoneurology of the Ministry of Healthcare of Moscow, 70 Michurinskiy Pr., Moscow, Russian Federation, 117343

³Tyumen oblast Center for Multiple Sclerosis of «Neftyanik» Medical Department, 19/1 50 years of VLKSM Str., Tyumen, Russian Federation, 625013 

Boyko A.N. ― D. Med. Sc., Professor of the Department of Neurology, Neurosurgery and Medical Genetics, Director of the Center for Demyelinating Diseases, tel. +7-903-729-29-81, e-mail: boykoan13@gmail.com

Bykova O.V. ― D. Med. Sc., neurologist, tel. +7-926-800-55-40, e-mail: avt496709@yandex.ru

Sivertseva S.A. ― D. Med. Sc., Head of the Tyumen Regional Medical Center, tel. +7-922-264-11-81, e-mail: sivertseva@gmail.com

 The review presents the possibilities of pathogenetic treatment of multiple sclerosis in children and adolescence under 18 y.o. The data on the use of disease modifying therapy (DMT) of first and second line were analyzed. All published studies of these drugs are observational, while several randomized studies of immunomodulatory drugs are still going on.

Key words: multiple sclerosis, treatment, children and adolescences.

REFERENCES

1. Banwell B., Bar-Or A., Giovannoni G., Dale R.C. and Tardieu M. Therapies for multiple sclerosis: considerations in the pediatric patient. Nat. Rev. Neurol, 2011, 7, pp. 109-22.
2. Ghezzi A., Banwell B., Boyko A., et al. The management of multiple sclerosis in children: a European view. Multiple sclerosis, 2010, 16, pp. 1258-1267.
3. Krupp L.B., Banwell B. and Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology, 2007, 68, pp. S7-12.
4. Mikaeloff Y., Moreau T., Debouverie M., et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J. Pediatr, 2001, 139, pp. 443-446.
5. Tenembaum S.N. and Segura M.J. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology, 2006, 67, pp. 511-513.
6. Waubant E., Hietpas J., Stewart T., et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics, 2001, 32, pp. 211-213.
7. Boyko A.N., Batysheva T.T., Bykova O.V. et al. Comparison of the efficacy and tolerability of beta-interferon-1a for intramuscular use in adults and adolescents with relapsing multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2012, 2 (2), pp. 98-103 (in Russ.).
8. Bykova O.V., Kuzenkova L.M., Vysotskaya L.M. et al. Interferon-beta-1b for immunomodulating treatment of multiple sclerosis in pediatric practice. Pediatricheskaya farmakologiya, 2006, 3 (6), pp. 35-38 (in Russ.).
9. Bykova O.V., Platonova A.N., Gol’tsova N.V. et al. Safety of the use of interferon-beta1 for subcutaneous administration in children and adolescents with multiple sclerosis. Voprosy sovremennoy pediatrii, 2008, 7 (3), pp. 108-112 (in Russ.).
10. Bykova O.V., Sidorenko T.V., Platonova A.N. et al. The use of interferon-beta-1a for intramuscular injection in children and adolescents with multiple sclerosis — efficacy, safety and adherence to therapy. Pediatricheskaya farmakologiya, 2009, 6 (5), pp. 14-19 (in Russ.).
11. Voloshina N.P., Egorkina O.V. Draft protocol for the treatment of pediatric multiple sclerosis. Mezhdunarodnyy nevrologicheskiy zhurnal, 2012, 8, pp. 1-54 (in Russ.).
12. Ghezzi A., Amato M.P., Capobianco M., et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple sclerosis (Houndmills, Basingstoke, England), 2005, 11, pp. 420-424.
13. Yeh E.A., Waubant E., Krupp L.B., et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch. Neurology, 2011, 68,pp. 437-444.
14. Gusev E., Boiko A., Bikova O., et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clinical Neurology & Neurosurgery, 2002, 104, pp. 203-207.
15. Boiko A., Vorobeychik G., Paty D., et al. the UBC MS Clinic Neurologists. Early onset multiple sclerosis: A longitudinal study. Neurology, 2002, 59, pp. 1006-1010.
16. Waldman A.T., Gorman M.P., Rensel M.R., et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. Journal of child neurology, 2011, 26, pp. 675-82.
17. Paty D.W., Boiko A.N,. Vorobeychik G.K. Multiple sclerosis with early and late disease onset. Chapter 18 in: “Multiple sclerosis 2. Blue book of Practical Neurology #27”, eds. W.I. McDonald and J.H. Noseworthy Elsevier Science, Butterworth Heinemann, Philadelphia, PA, 2003, pp. 285-302.
18. Amato M.P., Goretti B., Ghezzi A., et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology, 2010, 75, pp. 1134-1337.
19. Polman C.H., Bertolotto A., Deisenhammer F., et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol, 2010, 9, pp. 740-750.
20. Yeh E.A., Chitnis T., Krupp L., et al. Pediatric multiple sclerosis. Nat. Rev. Neurol, 2009, 5, pp. 621-631.
21. Lulu S., Julian L., Shapiro E., Hudson K., Waubant E. Treatment adherence and transitioning youth in pediatric multiple sclerosis. Multiple sclerosis and related disorders, 2014, 3, pp. 689-695.
22. Chitnis T., Tardieu M., Amato M.P., et al. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology, 2013, 80, pp. 1161-1168.
23. Borriello G., Prosperini L., Luchetti A. and Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur. J. Paediatr. Neurol, 2009, 13, pp. 67-71.
24. Huppke P., Stark W., Zurcher C., et al. Natalizumab use in pediatric multiple sclerosis. Arch. Neurol, 2008, 65, pp. 1655-1658.
25. Arnal-Garcia C., Garcia-Montero M.R., Malaga I., et al. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur. J. Paediatr. Neurol, 2013, 17, pp. 50-54.
26. Kornek B., Aboul-Enein F., Rostasy K., et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA neurology, 2013, 70, pp. 469-475.
27. Ghezzi A. Therapeutic strategies in childhood multiple sclerosis. Ther. Adv. Neurol. Disord, 2010, 3 (4), pp. 217-228.
28. Ghezzi A., Pozzilli C., Grimaldi L.M., et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult. Scler, 2013, 19, pp. 1106-1112.
29. Sivertseva S.A., Levitina E.V., Traykhil’ A.M. et al. The first Russian experience of using natalizumab for the treatment of a relapsing-remitting form of multiple sclerosis in children. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2014, 10 (2), pp. 92-98 (in Russ.).
30. Putzki N., Stich O., Gartzen K., et al. Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de-escalation and escalation. Eur. J. Neurol, 2010, 17, p. e105.
31. Hartung H.P., Gonsette R., Konig N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet, 2002, 360, pp. 2018-2025.
32. Marriott J.J., Miyasaki J.M., Gronseth G., O’Connor P.W., Therapeutics, Technology Assessment Subcommittee of the American Academy of N. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2010, 74, pp. 1463-1470.
33. Makhani N., Gorman M.P., Branson H.M., et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology, 2009, 72, pp. 2076-82.